The molecular mechanisms of melanoma tumorigenesis: An update

Giornale Italiano di Dermatologia e Venereologia

Volumn 142, Issue 2, 2007, Pages 71-82

  Gao, L ^a   Zhao, H ^a   Cornelius, L A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AKT; Genes, p53; Melanoma; MITF protein, human; PI 3K

Indexed keywords

B RAF KINASE; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAS PROTEIN;

CARCINOGENESIS; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MELANOMA; NONHUMAN; PATHOGENESIS; PHENOTYPE; REVIEW;

EID: 34250866796     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Miller AJ, Mihm MC, Jr. Melanoma. N Engl JMed 2006;355:51-65.
2. Merlino G, Noonan FP. Modeling gene-environment interactions in malignant melanoma. Trends Mol Med 2003;9:102-8.
3. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005;365:687-701.
4. Chudnovsky Y, Khavari PA, Adams AE. Melanoma genetics and the development of rational therapeutics. J Clin Invest 2005;115:813-24.
5. Cowan JM, Halaban R, Francke U. Cytogenetic analysis of melanocytes from premalignant nevi and melanomas. J Natl Cancer Inst 1988;80:1159-64.
6. Fountain JW, Karayiorgou M, Ernstoff MS, Kirkwood JM, Vlock DR, Titus-Ernstoff L et al. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A 1992;89:10557-61.
7. Petty EM, Bolognia JL, Bale AE, Yang-Feng T. Cutaneous malignant melanoma and atypical moles associated with a constitutional rearrangement of chromosomes 5 and 9. Am J Med Genet 1993;45:77-80.
8. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994;368:753-6.
9. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W et al. Analysis of the p 16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994;8:23-6.
10. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD et al. Germline p16 mutations in familial melanoma. Nat Genet 1994;8:15-21.
11. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
12. Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 2006;20:2149-82.
13. de Snoo FA, Hayward NK. Cutaneous melanoma susceptibility and progression genes. Cancer Lett 2005;230:153-86.
14. Liu L, Dilworth D, Gao L, Monzon J, Summers A, Lassam N et al. Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma. Nat Genet 1999;21:128-32.
15. Orlow I, Begg CB, Cotignola J, Roy P, Hummer AJ, Clas BA et al. CDKN2A Germline Mutations in Individuals with Cutaneous Malignant Melanoma. J Invest Dermatol 2007 in press.
16. MacKie RM, Andrew N, Lanyon WG, Connor JM. CDKN2A germline mutations in U.K. patients with familial melanoma and multiple primary melanomas. J Invest Dermatol 1998;111:269-72.
17. Harland M, Holland EA, Ghiorzo P, Mantelli M, Bianchi-Scarra G, Goldstein AM et al. Mutation screening of the CDKN2 A promoter in melanoma families. Genes Chromosomes Cancer 2000;28:45-57.
18. Petronzelli F, Sollima D, Coppola G, Martini-Neri ME, Neri G, Genuardi M. CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf) RNA processing in a melanoma/neurofibroma kindred. Genes Chromosomes Cancer 2001;31:398-401.
19. Loo JC, Liu L, Hao A, Gao L, Agatep R, Shennan M et al. Germline splicing mutations of CDKN2A predispose to melanoma. Oncogene 2003;22:6387-94.
20. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
21. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARE tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A 1998;95:8292-7.
22. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L et al. The Ink4a tumor suppressor gene product, p 19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998;92:713-23.
23. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998;92:725-34.
24. Sarkar-Agrawal P, Vergilis I, Sharpless NE, DePinho RA, Runger TM. Impaired processing of DNA photoproducts and ultraviolet hypermutability with loss of p16INK4a or p19ARF. J Natl Cancer Inst 2004;96:1790-3.
25. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996;85:27-37.
26. Krimpenfort P, Quon KC, Mooi WJ, Loonstra A, Berns A. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature 2001;413:83-6.
27. Sharpless NE, Bardeesy N, Lee KH, Carrasco D, Castrillon DH, Aguirre AJ et al. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 2001;413:86-91.
28. Kamijo T, Bodner S, van de Kamp E, Randle DH, Sherr CJ. Tumor spectrum in ARF-deficient mice. Cancer Res 1999;59:2217-22.
29. Sharpless NE, Ramsey MR, Balasubramanian P, Castrillon DH, DePinho RA. The differential impact of p16(TNK4a) or p19(ARF) deficiency on cell growth and tumorigenesis. Oncogene 2004;23:379-85.
30. Chin L, Pomerantz J, Polsky D, Jacobson M, Cohen C, Cordon-Cardo C et al. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev 1997;11:2822-34.
31. Pollock PM, Welch J, Hayward NK. Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development. Cancer Res 2001;61:1154-61.
32. Geffirotin C, Crechet F, Le Roy P, Le Chalony C, Leplat JJ, Iannuccelli N et al. Identification of five chromosomal regions involved in predisposition to melanoma by genome-wide scan in the MeLiM swine model. Int J Cancer 2004;110:39-50.
33. van der Velden PA, Sandkuijl LA, Bergman W, Hille ET, Frants RR, Gruis NA. A locus linked to p16 modifies melanoma risk in Dutch familial atypical multiple mole melanoma (FAMMM) syndrome families. Genome Res 1999;9:575-80.
34. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996;12:97-9.
35. Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A et al. Prevalence of p16 and CDK4 germline mutations in 48 melanomaprone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 1998;7:209-16.
36. Goldstein AM, Struewing JP, Chidambaram A, Fraser MC, Tucker MA. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst 2000;92:1006-10.
37. Sotillo R, Garcia JF, Ortega S, Martin J, Dubus P, Barbacid M et al. Invasive melanoma in Cdk4-targeted mice. Proc Natl Acad Sci U S A 2001;98:13312-7.
38. Gillanders E, Juo SH, Holland EA, Jones M, Nancarrow D, Freas-Lutz D et al. Localization of a novel melanoma susceptibility locus to 1p22. Am J Hum Genet 2003;73:301-13.
39. Bale SJ, Dracopoli NC, Tucker MA, Clark WH, Jr., Fraser MC, Stanger BZ et al. Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N Engl J Med 1989;320:1367-72.
40. Schuster EF, Stoger R. CHD5 defines a new subfamily of chromodomain-SWI2/SNF2-like helicases. Mamm Genome 2002;13:117-9.
41. Bagchi A, Papazoglu C, Wu Y, Capurso D, Brodt M, Francis D et al. CHD5 is a tumor suppressor at human 1p36. Cell 2007;128:459-75.
42. Poetsch M, Dittberner T, Woenckhaus C. Microsatellite analysis at 1p36.3 in malignant melanoma of the skin: fine mapping in search of a possible tumour suppressor gene region. Melanoma Res 2003; 13:29-33.
43. van der Velden PA, Sandkuijl LA, Bergman W, Pavel S, van Mourik L, Frants RR et al. Melanocoitin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. Am J Hum Genet 2001;69:774-9.
44. Box NF, Duffy DL, Chen W, Stark M, Martin NG, Sturm RA et al. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 2001;69:765-73.
45. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351:998-1012.
46. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003;63:756-9.
47. Li G, Schaider H, Satyamoorthy K, Hanakawa Y, Hashimoto K, Herlyn M. Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene 2001;20:8125-35.
48. Gray-Schopfer VC, da Rocha Dias S, Marais R. The role of B-RAF in melanoma. Cancer Metastasis Rev 2005;24:165-83.
49. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
50. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353(20):2135-47.
51. Pavey S, Johansson P, Packer L, Taylor J, Stark M, Pollock PM, et al. Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 2004;23:4060-7.
52. Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol 2005;15:249-54.
53. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006;439:358-62.
54. Grbovic OM, Basso AD, Sawai A, Ye Q, Friedlander P, Solit D et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci U S A 2006;103:57-62.
55. Takata M, Goto Y, Ichii N, Yamaura M, Murata H, Koga H et al. Constitutive activation of the mitogen-activated protein kinase signaling pathway in acral melanomas. J Invest Dermatol 2005;125:318-22.
56. Hattori M, Minato N. Rap1 GTPase: functions, regulation, and malignancy. J Biochem (Tokyo) 2003;134:479-84.
57. Gao L, Feng Y, Bowers R, Becker-Hapak M, Gardner J, Council L et al. Ras-associated protein-1 regulates extracellular signal-regulated kinase activation and migration in melanoma cells: two processes important to melanoma tumorigenesis and metastasis. Cancer Res 2006;66:7880-8.
58. Apicelli AJ, Uhlmann EJ, Baldwin RL, Ding H, Nagy A, Guha A et al. Role of the Rap1 GTPase in astrocyte growth regulation. Glia 2003;42:225-34.
59. Lau N, Uhlmann EJ, Von Lintig FC, Nagy A, Boss GR, Gutmann DH et al. Rap1 activity is elevated in malignant astrocytomas independent of tuberous sclerosis complex-2 gene expression. Int J Oncol 2003;22:195-200.
60. Gutmann DH, Saporito-Irwin S, DeClue JE, Wienecke R, Guha A. Alterations in the rap1 signaling pathway are common in human gliomas. Oncogene 1997;15:1611-6.
61. Altschuler DL, Ribeiro-Neto F. Mitogenic and oncogenic properties of the small G protein Rap1b. Proc Natl Acad Sci U S A 1998;95:7475-9.
62. Zhang Z, Mitra RS, Henson BS, Datta NS, McCauley LK, Kumar P et al. Rap1GAP inhibits tumor growth in oropharyngeal squamous cell carcinoma. Am J Pathol 2006;168:585-96.
63. Fischer U, Meltzer P, Meese E. Twelve amplified and expressed genes localized in a single domain in glioma. Hum Genet 1996;98:625-8.
64. Wienecke R, Konig A, DeClue JE. Identification of tuberin, the tuberous sclerosis-2 product. Tuberin possesses specific Rap1GAP activity. J Biol Chem 1995;270:16409-14.
65. Ishida D, Kometani K, Yang H, Kakugawa K, Masuda K, Iwai K et al. Myeloproliferative stem cell disorders by deregulated Rap1 activation in SPA-1-deficient mice. Cancer Cell 2003;4:55-65.
66. Goldstein AM, Goldin LR, Dracopoli NC, Clark WH, Jr., Tucker MA. Two-locus linkage analysis of cutaneous malignant melanoma/dysplastic nevi. Am J Hum Genet 1996;58:1050-6.
67. Dracopoli NC, Harnett P, Bale SJ, Stanger BZ, Tucker MA, Housman DE et al. Loss of alleles from the distal short arm of chromosome 1 occurs late in melanoma tumor progression. Proc Natl Acad Sci U S A 1989;86:4614-8.
68. Tsao H, Zhang X, Majewski P, Haluska FG. Mutational and expression analysis of the p73 gene in melanoma cell lines. Cancer Res 1999;59:172-4.
69. Wu H, Goel V, Haluska FG. PTEN signaling pathways in melanoma. Oncogene 2003;22:3113-22.
70. Isshiki K, Elder DE, Guerry D, Linnenbach AJ. Chromosome 10 allelic loss in malignant melanoma. Genes Chromosomes Cancer 1993;8:178-84.
71. Guldberg P, thor Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 1997;57:3660-3.
72. Tsao H, Zhang X, Benoit E, Haluska FG. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 1998;16:3397-402.
73. Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 2004;64:7002-10.
74. Dai DL, Martinka M, Li G. Prognostic significance of activated Akt expression in melanoma: a clinicopamologic study of 292 cases. J Clin Oncol 2005;23:1473-82.
75. Haluska FG, Tsao H, Wu H, Haluska FS, Lazar A, Goel V Genetic alterations in signaling pathways in melanoma. Clin Cancer Res 2006;12(7 Pt2):2301s-07s.
76. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006;6:184-92.
77. Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005;5:921-9.
78. Govindarajan B, Sligh JE, Vincent BJ, Li M, Canter JA, Nickoloff BJ et al. Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest 2007;117:719-29.
79. Levy C, Khaled M, Fisher DE. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med 2006; 12:406-14.
80. Steingrimsson E, Moore KJ, Lamoreux ML, Ferre-D'Amare AR, Burley SK, Zimring DC et al. Molecular basis of mouse microphthalmia (mi) mutations helps explain their developmental and phenotypic consequences. Nat Genet 1994;8:256-63.
81. Loercher AE, Tank EM, Delston RB, Harbour JW. MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J Cell Biol 2005;168:35-40.
82. Carreira S, Goodall J, Aksan I, La Rocca SA, Galibert MD, Denat L et al. Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 2005;433:764-9.
83. Wellbrock C, Marais R. Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. J Cell Biol 2005;170:703-8.
84. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005;436:117-22.
85. Carreira S, Goodall J, Denat L, Rodriguez M, Nuciforo P, Hoek KS et al. Mitf regulation of Dial controls melanoma proliferation and invasiveness. Genes Dev 2006;20:3426-39.
86. Carreira S, Liu B, Goding CR. The gene encoding the T-box factor Tbx2 is a target for the microphthalmia-associated transcription factor in melanocytes. J Biol Chem 2000;275:21920-7.
87. Vance KW, Carreira S, Brosch G, Goding CR. Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas. Cancer Res 2005;65:2260-8.
88. Du J, Widlund HR, Horstmann MA, Ramaswamy S, Ross K, Huber WE et al. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 2004;6:565-76.
89. Busca R, Berra E, Gaggioli C, Khaled M, Bille K, Marchetti B et al. Hypoxia-inducible factor 1{alpha} is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. J Cell Biol 2005;170:49-59.
90. McGill GG, Haq R, Nishimura EK, Fisher DE. c-Met expression is regulated by Mitf in the melanocyte lineage. J Biol Chem 2006;281:10365-73.
91. Kim M, Gans JD, Nogueira C, Wang A, Paik JH, Feng B et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 2006;125:1269-81.
92. Bastian BC, LeBoit PE, Hamm H, Brocker EB, Pinkel D. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 1998;58:2170-5.
93. Namiki T, Yanagawa S, Izumo T, Ishikawa M, Tachibana M, Kawakami Y et al. Genomic alterations in primary cutaneous melanomas detected by metaphase comparative genomic hybridization with laser capture or manual microdissection: 6p gains may predict poor outcome. Cancer Genet Cytogenet 2005;157:1-11.